GEN Exclusives

More »

GEN News Highlights

More »
Feb 28, 2007

Amsterdam Molecular Therapeutics Obtains License to AMT-020 for Acute Intermittent Porphyria

  • Amsterdam Molecular Therapeutics  (AMT) obtained exclusive, worldwide rights to develop and commercialize AMT-020 as a therapeutic product from UTE CIMA, Proyecto de Biomedicina CIMA, and Digna Biotech (all part of the University of Navarra, Pamplona, Spain). 

    The license allows AMT to initiate the clinical development of AMT-020 to treat acute intermittent porphyria. AMT-020 is an AAV vector gene therapy containing the porphobilinogen deaminase gene, which encodes for the enzyme that is defective in acute intermittent porphyria. This disease is associated with recurrent attacks of abdominal pain, gastrointestinal dysfunction, and neurologic disturbances.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?